Past Updates from the Clinician Registry Listserv
Update Sent August 13, 2007
NOTE: This document is provided for historical purposes only and may not provide our most accurate and up-to-date information. The most current Clinician's information can be found on the Clinician Home Page.
Today's topics Include:
- COCA Conference Call
- Influenza
- Pandemic Influenza
- Avian Influenza
- Dengue and Dengue Hemorrhagic Fever
- ACIP Revised Recommendation - Meningococcal Conjugate Vaccine
COCA Conference Call
Please join us for our next COCA Conference Call!
Title: West Nile Update, 2007
Speakers: Emily C. Zielinski-Gutierrez, DrPH and Carolyn Reimann, MD
Date: Thursday, August 23, 2007
Time: 1:00 - 2:00 p.m. ET
Dial-in Number: 800-857-3796
Passcode: COCA
Objectives
1)Review basic WNV history, transmission and disease manifestations
2)Discuss temporal and geographic trends of WNV in the US
3)Discuss WNV prevention measures
Speaker Information
Emily Zielinski-Gutiérrez, MPH, Dr.P.H. is a Behavioral Scientist with the CDC Division of Vector-Borne Infectious Diseases, located in Fort Collins, Colorado. Dr. Zielinski-Gutierrez coordinates national education efforts for West Nile virus and several other vector-borne diseases, works with dengue fever in the Pacific and conducts research to improve disease prevention activities. She holds doctoral and masters degrees in public health from the Tulane School of Public Health and Tropical Medicine in New Orleans where her studies included medical anthropology, tropical medicine, epidemiology and health communication. She has worked internationally in reproductive health and dengue fever prevention, and domestically with bioterrorism issues, HIV, hospice and border health. Dr. Zielinski-Gutierrez’s interests include evaluation of infectious disease control, the role for community participation and culture in public health prevention, and the role of human ecology in understanding vector-borne disease.
Carolyn Reimann, MD completed her undergraduate degree in biomedical engineering at Tulane University in New Orleans, LA, in 1997. She then graduated from the Uniformed Services University of the Health Sciences in Bethesda, MD, in 2001. She completed a family medicine residency at Bremerton Naval Hospital in Washington state in 2004, followed by working for two years at Naval Hospital Yokosuka, Japan, as an ER physician. Carolyn is currently in her second year of a preventive medicine residency / Master of Science in Public Health program at the University of Colorado Health Sciences Center in Denver. She is presently working on her thesis in the Arboviral Diseases Branch of the Division of Vector-Borne Infectious Diseases at the CDC office in Ft. Collins.
Slides will be available next week on the COCA Web site: http://www.bt.cdc.gov/coca/callinfo.asp
Influenza
Update: Influenza Activity - United States and Worldwide, 2006-07 Season, and Composition of the 2007-08 Influenza Vaccine - MMWR Weekly - August 10During the 2006-07 season, influenza activity peaked in mid-February in the United States and was associated with less mortality and lower rates of pediatric hospitalizations than during the previous three seasons. In the United States, influenza A (H1) viruses predominated overall, but influenza A (H3) viruses were isolated more frequently than influenza A (H1) viruses late in the season. Although influenza A (H1), A (H3), and B viruses cocirculated worldwide, influenza A (H3) viruses were the most commonly reported type in Europe and Asia. Sporadic cases of avian influenza A (H5N1) virus infections associated with severe illness or death were reported among humans in Cambodia, China, Egypt, Indonesia, Laos, Nigeria, and Viet Nam. This report summarizes influenza activity in the United States and worldwide during the 2006--07 influenza season (October 1, 2006--May 19, 2007) and describes the composition of the 2007--08 influenza vaccine.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a2.htm
Pandemic Influenza
Community Measures Prevent Deaths During Pandemic, New Study Finds - CDC Press Release - August 7The findings, which are published in the Aug. 8 issue of the Journal of the American Medical Association, provide vital clues to help public officials planning for the next influenza pandemic and highlight the importance of community strategies. These strategies are particularly important because the intervention most likely to provide the best protection against pandemic influenza -- a vaccine -- is unlikely to be available at the outset of a pandemic. Community strategies that delay or reduce the impact of a pandemic (also called non-pharmaceutical interventions) may help reduce the spread of disease until a vaccine that is well-matched to the virus is available.
http://www.cdc.gov/od/oc/media/pressrel/2007/r070807.htm
For more information about community strategies for pandemic influenza, please visit: http://www.pandemicflu.gov/plan/community/community_mitigation.pdf.
Avian Influenza
NIH Scientists Target Future Pandemic Strains of H5N1 Avian Influenza - NIH Press Release - August 9Led by Gary Nabel, M.D., Ph.D., director of the NIAID’s Dale and Betty Bumpers Vaccine Research Center (VRC), the team is reporting in the August 10, 2007 issue of the journal Science that they have developed a strategy to generate vaccines and therapeutic antibodies that could target predicted H5N1 mutants before these viruses evolve naturally. This advance was made possible by creating mutations in the region of the H5N1 hemagglutinin (HA) protein that directs the virus to bird or human cells and eliciting antibodies to it.
http://www.nih.gov/news/pr/aug2007/niaid-09.htm
Dengue and Dengue Hemorrhagic Fever
Dengue Hemorrhagic Fever - U.S.-Mexico Border, 2005 - MMWR Weekly - August 10
This report summarizes the results of that investigation, which determined that the percentage of DHF cases associated with dengue fever outbreaks at the Texas-Tamaulipas border has increased. Health-care providers along the U.S. border with Mexico should be vigilant for DHF and familiar with its diagnosis and management to reduce the number of severe illnesses and deaths associated with outbreaks of dengue fever.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a1.htm
Outbreak Notice Update: Dengue, Tropical and Subtropical Regions - August 7
Dengue has become one of the most common viral diseases transmitted to humans by the bite of infected mosquitoes (usually Aedes aegypti); it is the most common cause of fever in travelers returned from the Caribbean, Central America, and South Central Asia. Symptoms of dengue include fever, severe headache, retro-orbital eye pain (pain behind the eye), joint and muscle pain, and rash. Dengue can produce a range of illness from mild to severe, as well as fatal hemorrhagic fever. Travelers are at risk for dengue infection if they travel to or reside in areas where dengue virus is transmitted; the preventive measures outlined in the following link can reduce their risk.
http://wwwn.cdc.gov/travel/contentDengueTropicalSubTropical.aspx
Dengue and Dengue Hemorrhagic Fever: Information for Health Care Practitioners
http://www.cdc.gov/ncidod/dvbid/dengue/dengue-hcp.htm
Meningococcal Conjugate Vaccine
Revised Recommendations of the Advisory Committee on Immunization Practices to Vaccinate All Persons Aged 11--18 Years with Meningococcal Conjugate Vaccine - MMWR Notice to Readers - August 10
In June 2007, ACIP revised its recommendation to include routine vaccination of all persons aged 11--18 years with 1 dose of MCV4 at the earliest opportunity. Persons aged 11--12 years should be routinely vaccinated at the 11--12 years health-care visit as recommended by ACIP (2). ACIP continues to recommend routine vaccination for persons aged 19--55 years who are at increased risk for meningococcal disease: college freshmen living in dormitories, microbiologists routinely exposed to isolates of Neisseria meningitidis, military recruits, travelers to or residents of countries in which N. meningitidis meningitis is hyperendemic or epidemic, persons with terminal complement component deficiencies, and persons with anatomic or functional asplenia.
http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5631a3.htm
The CDC and HHS logos are the exclusive property of the Department of Health and Human Services and may not be used for any purpose without prior express written permission. Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.
Links to non-Federal organizations are provided solely as a service to our users. Links do not constitute an endorsement of any organization by CDC or the Federal Government, and none should be inferred. The CDC is not responsible for the content of the individual organizations.
Please visit the COCA web page for additional information: http://www.bt.cdc.gov/coca/.
Our Clinician Communication Team is committed to excellence in reporting our weekly updates. Please e-mail coca@cdc.gov should you note any written errors or discrepancies.
If you need to unsubscribe or update your information, please go to our website: http://www.bt.cdc.gov/clinregistry
If you need further information or technical help, please send an e-mail message to: coca@cdc.gov
Page last modified August 13, 2007
Content Source:
- Coordinating Center for Health Information and Service (CCHIS)
National Center for Health Marketing (NCHM)
Division of Health Communication and Marketing (DHCM)
Emergency Communication System (ECS)